Literature DB >> 26852138

Methylphenidate and emotional-motivational processing in attention-deficit/hyperactivity disorder.

Annette Conzelmann1,2, Eva Woidich3, Ronald F Mucha3, Peter Weyers3, Mathias Müller3, Klaus-Peter Lesch4, Christian P Jacob4, Paul Pauli5.   

Abstract

In line with the assumption that emotional-motivational deficits are one core dysfunction in ADHD, in one of our previous studies we observed a reduced reactivity towards pleasant pictures in adult ADHD patients as compared to controls. This was indicated by a lack of attenuation of the startle reflex specifically during pleasant pictures in ADHD patients. The first choice medical agents in ADHD, methylphenidate (MPH), is discussed to normalize these dysfunctions. However, experimental evidence in the sense of double-blind placebo-controlled study designs is lacking. Therefore, we investigated 61 adult ADHD patients twice, one time with placebo and one time with MPH with the same experimental design as in our study previously and assessed emotion processing during the presentation of pleasant, neutral and unpleasant pictures. We obtained startle reflex data as well as valence and arousal ratings in association with the pictures. As previously shown, ADHD patients showed a diminished startle attenuation during pleasant pictures while startle potentiation during unpleasant pictures was normal. Valence and arousal ratings unsuspiciously increased with increasing pleasantness and arousal of the pictures, respectively. There were no significant influences of MPH. The study replicates that ADHD patients show a reduced reactivity towards pleasant stimuli. MPH did not normalize this dysfunction. Possibly, MPH only influences emotions during more complex behavioural tasks that involve executive functions in adults with ADHD. Our results emphasize the importance for the use of double-blind placebo-controlled designs in psychopharmacological research.

Entities:  

Keywords:  ADHD; Adults; Emotion; Methylphenidate; Startle reflex

Mesh:

Substances:

Year:  2016        PMID: 26852138     DOI: 10.1007/s00702-016-1512-y

Source DB:  PubMed          Journal:  J Neural Transm (Vienna)        ISSN: 0300-9564            Impact factor:   3.575


  43 in total

1.  Affective startle modulation in clinical depression: preliminary findings.

Authors:  N B Allen; J Trinder; C Brennan
Journal:  Biol Psychiatry       Date:  1999-08-15       Impact factor: 13.382

2.  A review of fronto-striatal and fronto-cortical brain abnormalities in children and adults with Attention Deficit Hyperactivity Disorder (ADHD) and new evidence for dysfunction in adults with ADHD during motivation and attention.

Authors:  Ana Cubillo; Rozmin Halari; Anna Smith; Eric Taylor; Katya Rubia
Journal:  Cortex       Date:  2011-04-27       Impact factor: 4.027

Review 3.  The dopamine transporter and attention-deficit/hyperactivity disorder.

Authors:  Bertha K Madras; Gregory M Miller; Alan J Fischman
Journal:  Biol Psychiatry       Date:  2005-01-05       Impact factor: 13.382

4.  Effects of stimulant medication, incentives, and event rate on reaction time variability in children with ADHD.

Authors:  Jeffery N Epstein; William B Brinkman; Tanya Froehlich; Joshua M Langberg; Megan E Narad; Tanya N Antonini; Keri Shiels; John O Simon; Mekibib Altaye
Journal:  Neuropsychopharmacology       Date:  2011-01-19       Impact factor: 7.853

5.  Atomoxetine and nicotine enhance prepulse inhibition of acoustic startle in C57BL/6 mice.

Authors:  Thomas J Gould; Margaret Rukstalis; Michael C Lewis
Journal:  Neurosci Lett       Date:  2004-12-19       Impact factor: 3.046

6.  Methylphenidate treatment during pre- and periadolescence alters behavioral responses to emotional stimuli at adulthood.

Authors:  Carlos A Bolaños; Michel Barrot; Olivier Berton; Deanna Wallace-Black; Eric J Nestler
Journal:  Biol Psychiatry       Date:  2003-12-15       Impact factor: 13.382

7.  Stimulant rebound: how common is it and what does it mean?

Authors:  Gabrielle A Carlson; Kevin L Kelly
Journal:  J Child Adolesc Psychopharmacol       Date:  2003       Impact factor: 2.576

8.  Ventro-striatal reductions underpin symptoms of hyperactivity and impulsivity in attention-deficit/hyperactivity disorder.

Authors:  Susanna Carmona; Erika Proal; Elseline A Hoekzema; Juan-Domingo Gispert; Marisol Picado; Irene Moreno; Juan Carlos Soliva; Anna Bielsa; Mariana Rovira; Joseph Hilferty; Antonio Bulbena; Miquel Casas; Adolf Tobeña; Oscar Vilarroya
Journal:  Biol Psychiatry       Date:  2009-07-03       Impact factor: 13.382

Review 9.  Effects of methylphenidate on the catecholaminergic system in attention-deficit/hyperactivity disorder.

Authors:  Timothy E Wilens
Journal:  J Clin Psychopharmacol       Date:  2008-06       Impact factor: 3.153

10.  Agomelatine facilitates positive versus negative affective processing in healthy volunteer models.

Authors:  Catherine J Harmer; Christian de Bodinat; Gerard R Dawson; Colin T Dourish; Lara Waldenmaier; Sally Adams; Philip J Cowen; Guy M Goodwin
Journal:  J Psychopharmacol       Date:  2010-07-21       Impact factor: 4.153

View more
  1 in total

1.  Integrative genomic analysis of methylphenidate response in attention-deficit/hyperactivity disorder.

Authors:  Mireia Pagerols; Vanesa Richarte; Cristina Sánchez-Mora; Paula Rovira; María Soler Artigas; Iris Garcia-Martínez; Eva Calvo-Sánchez; Montse Corrales; Bruna Santos da Silva; Nina Roth Mota; Marcelo Moraes Victor; Luis Augusto Rohde; Eugenio Horacio Grevet; Claiton Henrique Dotto Bau; Bru Cormand; Miguel Casas; Josep Antoni Ramos-Quiroga; Marta Ribasés
Journal:  Sci Rep       Date:  2018-01-30       Impact factor: 4.379

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.